Abide Therapeutics

Neuropore Therapies, Inc. is a San Diego-based biopharmaceutical company dedicated to discovering innovative therapeutics that target the underlying causes of neurodegenerative diseases, with the mission of halting their progression. Their current clinical trials include the Phase 2 study of UCB0599 in patients with early-stage Parkinson's disease, and they have recently received a substantial grant from The Michael J. Fox Foundation for Parkinson's Research to support the development of their TLR2 program. With a team of experts and strategic partnerships with corporate foundations and academic institutions, Neuropore Therapies is well-positioned to make significant advancements in the field of neurodegenerative disease research. Their publications highlight the promising effects of their small molecule, NPT200-11, in a transgenic mouse model of Parkinson's disease, demonstrating their commitment to finding potential therapeutic solutions. Located in San Diego, California, Neuropore Therapies is dedicated to making a positive impact on the lives of individuals affected by neurodegenerative diseases.Generated from the website

Ligand Pharmaceuticals Inc., based in San Diego, CA, is a specialist in healthcare investing, focusing on the clinical development and commercialization of high-value medicines. The company boasts one of the largest and most diverse portfolios of biopharmaceutical royalties, featuring over 90 partnered commercial and development stage programs across various disease areas, including cancer and rare conditions. In addition to its royalty portfolio, Ligand maintains and licenses its proprietary technology platforms, Captisol and NITRICIL, to a wide network of biopharmaceutical partners, including major pharmaceutical manufacturers globally. The company's economic rights extend to more than 30 commercial programs marketed in over 70 countries, illustrating its significant impact in advancing tomorrow's medicines through technology and financial solutions. Generated from the website

Ambrx is a biopharmaceutical company that develops a range of protein-based drugs. Its ReCODE technology is used in multiple protein applications, including cytokines, peptides and antibodies. The company s technology is also helpful in various therapeutic areas. Its protein medicinal chemistry combines the power of medicinal chemistry with recombinant biosynthesis. The company also optimizes the pharmaceutical properties of lead candidate proteins. Located in La Jolla, Calif., Ambrx owns and controls a comprehensive intellectual property portfolio that dominates the incorporation of nonnative amino acids into biosynthetic proteins. The company is also an exclusive commercial licensee under the intellectual property rights owned by The Scripps Research Institute.